Aiji Miyashita
Overview
Explore the profile of Aiji Miyashita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
138
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shimamura M, Miyakawa J, Doi M, Okada K, Kurumatani H, Mori Y, et al.
J Clin Pharmacol
. 2016 Sep;
57(4):524-535.
PMID: 27681484
The purpose of the present study was to evaluate the pharmacokinetics of beraprost sodium (BPS) and its active enantiomer, BPS-314d, in Japanese subjects with impaired kidney function. The plasma and...
2.
Sato Y, Nagata M, Tetsuka K, Tamura K, Miyashita A, Kawamura A, et al.
Drug Metab Dispos
. 2014 Mar;
42(5):885-9.
PMID: 24595681
The aim of this study was to optimize methods for quantifying 13 uridine 5'-diphosphate-glucuronosyltransferase (UGT) isoforms (UGT1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, 2B15, and 2B17)...
3.
Matsumura H, Takagi K, Seki H, Ono Y, Ichinose S, Masuko H, et al.
Hypertens Pregnancy
. 2013 Oct;
33(1):93-101.
PMID: 24131296
Objective: To assess nicardipine safety for fetuses and neonates. Methods: Nicardipine was measured in maternal plasma (MP), umbilical cord arterial (UaP) and venous (UvP) plasma and breast milk (BrM) of...
4.
Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, et al.
Mol Pharm
. 2013 Apr;
10(5):1783-94.
PMID: 23560393
Mirabegron, a weak-basic compound, is a potent and selective β3-adrenoceptor agonist for the treatment of overactive bladder. Mirabegron extended release formulation shows dose-dependent oral bioavailability in humans, which is likely...
5.
Hashimoto T, Suzuki K, Kihara Y, Iwatsubo T, Miyashita A, Heeringa M, et al.
Xenobiotica
. 2012 Nov;
43(6):534-47.
PMID: 23167531
1. The absorption, metabolism and excretion of darexaban (YM150), a novel oral direct factor Xa inhibitor, were investigated after a single oral administration of [(14)C]darexaban maleate at a dose of...
6.
Takusagawa S, Miyashita A, Iwatsubo T, Usui T
Xenobiotica
. 2012 Jul;
42(12):1187-96.
PMID: 22834478
The potential for mirabegron, a β(3)-adrenoceptor agonist for the treatment of overactive bladder, to cause drug-drug interactions via inhibition or induction of cytochrome P450 (CYP) enzymes was investigated in vitro....
7.
Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T
Xenobiotica
. 2012 Apr;
42(10):957-67.
PMID: 22509825
1. Human cytochrome P450 (CYP) enzymes and esterases involved in the metabolism of mirabegron, a potent and selective human β(3)-adrenoceptor agonist intended for the treatment of overactive bladder, were identified...
8.
Sato Y, Miyashita A, Iwatsubo T, Usui T
Drug Metab Dispos
. 2012 Apr;
40(7):1389-96.
PMID: 22504157
The aims of this study were to develop a robust method for simultaneous quantification of carboxylesterases (CESs) 1 and 2 and to quantify those absolute protein levels in human liver...
9.
Sato Y, Nagata M, Kawamura A, Miyashita A, Usui T
Xenobiotica
. 2012 Mar;
42(9):823-9.
PMID: 22435749
The aims of this study were to quantify absolute protein levels of uridine 5'-diphosphate-glucuronosyltransferases (UGTs) 1A1 and 2B7 in human liver microsomes (HLMs) and to investigate their correlation with marker...
10.
Shiraga T, Yajima K, Teragaki T, Suzuki K, Hashimoto T, Iwatsubo T, et al.
Biol Pharm Bull
. 2012 Mar;
35(3):413-21.
PMID: 22382330
Darexaban maleate is a novel oral direct factor Xa inhibitor. Darexaban glucuronide (YM-222714) was the major component in plasma after oral administration of darexaban to humans and is the pharmacologically...